시장보고서
상품코드
1631521

내시경 점막하 박리술 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 적응증별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Endoscopic Submucosal Dissection Market Size, Share & Trends Analysis Report By Product (Gastroscopes And Colonoscopes), By Indication (Stomach Cancer), By End use (Hospitals), By Region, And Segment Forecasts, 2025 - 2030

발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

시장 규모 및 동향

전 세계 내시경적 점막하 박리술 시장 규모는 2024년 3억 7,040만 달러로 평가되며, 2025-2030년 동안 연평균 5.5%로 성장할 것으로 예상됩니다. 소화기암 및 기타 관련 질환의 유병률 증가, 내시경 기술 및 기기의 발전, 내시경적 점막하 박리술(ESD)과 같은 진단 및 치료 시술에 대한 수요를 주도하고 있습니다. 세계암연구기금 인터내셔널에 따르면 위암은 세계에서 5번째로 많은 암으로 남성은 4위, 여성은 7위이며, 2022년에는 96만 8,784명 이상의 환자가 새로 발생했는데, 중국이 35만 8,672명으로 가장 높은 발생률을 보고하고 있습니다. 식도암, 위암, 대장암의 발병률이 전 세계적으로 지속적으로 증가함에 따라 ESD를 포함한 첨단 시술의 필요성은 더욱 커지고 있습니다.

또한, 전 세계 고령화는 ESD 수요를 증가시키는 결정적인 요인입니다. 세계 인구의 고령화에 따라 암을 포함한 노화 관련 소화기 질환의 증가가 예상됩니다. 미국 암 협회에 따르면 위암은 노인에게 많이 발생하며, 진단 시 평균 연령은 68세이며, 매년 진단되는 10명 중 6명이 65세 이상입니다. 고령의 환자들은 합병증이 있는 경우가 많고, 기존 수술의 위험성이 높기 때문에 ESD를 포함한 최소침습적 치료법이 선호되고 있습니다.

고화질 내시경의 개발, 전기 수술용 칼의 개선, 영상 진단 기술의 향상으로 ESD 시술의 정확성과 안전성이 크게 향상되었습니다. 이러한 기술 혁신은 치료 효과를 향상시키고, ESD의 적응증을 확대하여 보다 광범위한 병변에 사용할 수 있게 되었습니다. 또한, 내시경 치료에 인공지능과 머신러닝을 도입하여 진단 정확도와 치료 성적을 향상시켜 시장 성장을 더욱 촉진하고 있습니다. 예를 들어, 2020년 9월, 올림푸스(Olympus Corporation)는 AI가 탑재된 대장내시경 검사 플랫폼 'ENDO-AID'를 출시하여 의심스러운 병변을 실시간으로 표시할 수 있도록 했습니다.

ESD 기술에 대한 의료 전문가들의 인식 개선과 교육 프로그램도 시장 확대에 기여하고 있으며, ESD에 대한 소화기내과 의사와 외과 의사의 숙련도가 향상되고, 특히 과거에는 접근성이 제한적이었던 지역에서 이 첨단 시술의 보급과 실현 가능성이 높아지고 있습니다. 다양한 의료 협회와 의료기관이 전문 교육 및 인증 프로그램을 제공하고 있으며, ESD에 대한 지식과 전문 지식을 보급하는 데 도움을 주고 있습니다. 예를 들어, 2024년 4월 FUJIFILM Healthcare Europe GmbH는 경구 내시경 근절개술(POEM)과 내시경 점막하 박리술(ESD)을 수행하기 위해 설계된 혁신적인 교육용 모델 EndoGel을 발표했습니다. 이 시뮬레이터는 두 가지 버전으로 제공되며, 이러한 복잡한 시술에 관여하는 인체 조직의 질감을 정확하게 재현하여 임상의에게 실제와 같은 훈련 경험을 제공합니다. 또한 고주파 장비를 포함하여 POEM 및 ESD 시술에 일반적으로 사용되는 다양한 의료 장비와 호환됩니다. 내시경 전문가와 의료기관의 비용 효율성을 높이기 위해 특별히 설계되었으며, 현실적인 시뮬레이션 교육을 통해 숙련도와 환자 결과를 향상시키는 것을 목표로 합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 내시경 점막하 박리술 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 상부 시장 전망
    • 보조 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
    • 산업 분석 - Porter's Five Forces 분석
    • PESTEL 분석

제4장 내시경 점막하 박리술 시장 : 제품별, 추정·동향 분석

  • 부문 대시보드
  • 내시경 점막하 박리술 시장 : 제품 변동 분석, 2024년과 2030년
    • 위내시경과 대장 카메라
    • 나이프
    • 주사제
    • 조직 리트랙터
    • 그래스퍼/클립
    • 기타

제5장 내시경 점막하 박리술 시장 : 적응증별, 추정·동향 분석

  • 부문 대시보드
  • 내시경 점막하 박리술 시장 : 적응증 변동 분석, 2024년과 2030년
    • 위암
    • 대장암
    • 식도암

제6장 내시경 점막하 박리술 시장 : 최종 용도별, 추정·동향 분석

  • 부문 대시보드
  • 내시경 점막하 박리술 시장 : 최종 용도 변동 분석, 2024년과 2030년
    • 병원
    • 외래 시설

제7장 내시경 점막하 박리술 시장 : 지역별, 추정·동향 분석

  • 지역별 시장 점유율 분석, 2024년과 2030년
  • 지역별 시장 대시보드
  • 세계 지역 시장 현황
  • 시장 규모, 예측 동향 분석, 2018-2030년
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제8장 경쟁 구도

  • 주요 시장 진출 기업의 최근 동향과 영향 분석
  • 기업/경쟁 분류
  • 시장 상황 분석, 2024년
  • 기업 개요
    • Olympus Corporation
    • Boston Scientific Corporation
    • FUJIFILM Holdings Corporation
    • Creo Medical
    • Medtronic PLC
    • HOYA Corporation
    • KARL STORZ SE &Co. KG
    • CONMED Corporation
    • Steris PLC
    • Taewoong Medical
    • Micro-tech Endoscopy
    • Cook Group
ksm 25.03.07

Market Size & Trends:

The global endoscopic submucosal dissection market size was valued at USD 370.4 million in 2024 and is projected to grow at a CAGR of 5.5% from 2025 to 2030. The increasing prevalence of gastrointestinal cancers and other related disorders and advancements in endoscopic technology & instrumentation drive the demand for diagnostic and therapeutic procedures such as endoscopic submucosal dissection (ESD). According to the World Cancer Research Fund International, stomach cancer is the fifth most common cancer worldwide, ranking fourth in men and seventh in women, with over 968,784 new cases in 2022, with China reporting the highest incidence at 358,672 cases. As esophageal, gastric, and colorectal cancer rates continue to rise globally, the need for advanced procedures, including ESD, becomes more persistent.

Furthermore, the aging population worldwide is a crucial factor boosting the demand for ESD. As the global population grows older, age-related gastrointestinal conditions, including cancers, are expected to rise. According to the American Cancer Society, gastric cancer, predominantly affects older individuals, with an average age of 68 when diagnosed, and 6 out of 10 diagnosed annually are 65 or older. Older patients often have comorbidities that make traditional surgery riskier, thereby increasing the preference for less invasive options including ESD.

The development of high-definition endoscopes improved electrosurgical knives, and enhanced imaging techniques have significantly increased the precision and safety of ESD procedures. These technological innovations have improved the efficacy of the treatment and expanded the indications for ESD, allowing it to be used for a broader range of lesions. Moreover, integrating artificial intelligence and machine learning in endoscopic procedures enhances diagnostic accuracy and procedural outcomes, further propelling market growth. For instance, in September 2020, Olympus Corporation launched an AI-powered colon endoscopy platform, ENDO-AID, that allows real-time display of detected suspicious lesions.

The growing awareness and training programs for healthcare professionals in ESD techniques also contribute to market expansion. The proficiency of gastroenterologists and surgeons in ESD has been increasing, enhancing both the reach and feasibility of this advanced procedure, particularly in areas that previously had limited access to such treatments. Various medical societies and institutions offer specialized training and certification programs, which are instrumental in disseminating knowledge and expertise in ESD. For instance, in April 2024, FUJIFILM Healthcare Europe GmbH introduced EndoGel, an innovative training model designed for performing Peroral Endoscopic Myotomy (POEM) and Endoscopic Submucosal Dissection (ESD) procedures. This simulator comes in two versions and accurately replicates the texture of human tissue involved in these complex procedures, offering clinicians a realistic training experience. It is also compatible with a range of medical devices typically used in POEM and ESD procedures, including high-frequency devices. It is specifically engineered to be cost-effective for endoscopy professionals and healthcare institutions, aiming to enhance proficiency and patient outcomes through realistic simulation training.

Global Endoscopic Submucosal Dissection Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the endoscopic submucosal dissection market on the basis of product, indication, end use, and regions.

  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Gastroscopes and Colonoscopes
  • Knives
  • Injection Agents
  • Tissue Retractors
  • Graspers/ Clips
  • Other Products
  • Indication Outlook (Revenue, USD Million, 2018 - 2030)
  • Stomach Cancer
  • Colon Cancer
  • Esophageal Cancer
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Outpatient Facilities
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Indication
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Indication Outlook
    • 2.2.3. End Use Outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Endoscopic Submucosal Dissection Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Industry Analysis - Porter's Five Forces
      • 3.2.3.1. Bargaining power of the suppliers
      • 3.2.3.2. Bargaining power of the buyers
      • 3.2.3.3. Threats of substitution
      • 3.2.3.4. Threats from new entrants
      • 3.2.3.5. Competitive rivalry
    • 3.2.4. PESTEL Analysis
      • 3.2.4.1. Political landscape
      • 3.2.4.2. Economic and Social landscape
      • 3.2.4.3. Technological landscape

Chapter 4. Endoscopic Submucosal Dissection Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Endoscopic Submucosal Dissection Market: Product Movement Analysis, 2024 & 2030 (USD Million)
    • 4.2.1. Gastroscopes and Colonoscopes
      • 4.2.1.1. Gastroscopes and Colonoscopes Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2. Knives
      • 4.2.2.1. Knives Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.3. Injection Agents
      • 4.2.3.1. Injection Agents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.4. Tissue Retractors
      • 4.2.4.1. Tissue Retractors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.5. Graspers/ Clips
      • 4.2.5.1. Graspers/ Clips Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.6. Other Products
      • 4.2.6.1. Other Products Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Endoscopic Submucosal Dissection Market: Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Endoscopic Submucosal Dissection Market: Indication Movement Analysis, 2024 & 2030 (USD Million)
    • 5.2.1. Stomach Cancer
      • 5.2.1.1. Stomach Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. Colon Cancer
      • 5.2.2.1. Colon Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Esophageal Cancer
      • 5.2.3.1. Esophageal Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Endoscopic Submucosal Dissection Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Endoscopic Submucosal Dissection Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
    • 6.2.1. Hospitals
      • 6.2.1.1. Hospitals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. Outpatient Facilities
      • 6.2.2.1. Outpatient Facilities Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Endoscopic Submucosal Dissection Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Market Position Analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Olympus Corporation
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Boston Scientific Corporation
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. FUJIFILM Holdings Corporation
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Creo Medical
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Medtronic PLC
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. HOYA Corporation
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. KARL STORZ SE & Co. KG
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. CONMED Corporation
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Steris PLC
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Taewoong Medical
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Micro-tech Endoscopy
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. Cook Group
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Product benchmarking
      • 8.4.12.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제